Novartis India Share Price
Free Demat with Zero AMC*
+ Free 1st Year AMC
Summary
The stock has recorded a trading volume of 8,798 shares,. Its Average Traded Price (ATP) is ₹1925.09, while the Last Traded Quantity at the Last Traded Price (LTQ@LTP) is 5 @ ₹1923.00.
Novartis India has an upper circuit limit of ₹2110.90 and a lower circuit limit of ₹1727.10. The total value traded stands at ₹1.69 CR, and the delivery percentage for the day is 40.6%.
The stock is currently traded with a market lot size of 1. Novartis India also offers a dividend yield of 0%.
Novartis India Share Price Chart
Novartis India Share Key Metrics
Volume
8798.00
Market Cap
4738.16 CR
LTQ@LTP
5@1923.00
ATP
1925.09
Var Margin
23.96 %
Circuit Range
1727.1-2110.9
Delivery %
40.6 %
Value
1.69 CR
ASM/GSM
No
Market Lot
1
Novartis India Resistance and Support
Pivot 1953.23
Resistance
First Resistance
1996.46
Second Resistance
2073.93
Third Resistance
2117.16
Support
First Support
1875.76
Second Support
1832.53
Third Support
1755.06
Novartis India Shareholding Pattern
View More- 2016-17
- 2018-19
- 2019-20
- 2020-21
- 2021-22
- 2022-23
- 2023-24
- 2024-25
- 2025-26
- 2026-27
Total Promoters
Novartis India Corporate Actions
| Date | Agenda |
|---|---|
| 2026-07-23 | Quarterly Results |
| 2025-10-28 | Quarterly Results |
| 2026-05-12 | Audited Results |
| 2026-01-28 | Quarterly Results |
| 2025-07-29 | Quarterly Results |
| 2025-05-09 | Audited Results & Final Dividend |
| 2025-01-28 | Quarterly Results |
| 2024-10-25 | Quarterly Results |
| Ex Date | Record Date | |
|---|---|---|
| 2025-07-23 | 2025-07-23 | View More |
Novartis India News
Novartis India Ltd - 500672 - Board Meeting Intimation for Consideration And Approval Of The Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2026.
Novartis board to meet on November 3, 2026, for financial results. The results pertain to the quarter and half-year ended September 30, 2026.
Sep 30 2026 19:29:21
Novartis India Ltd - 500672 - Closure of Trading Window
Novartis board will meet on November 3, 2026, for financial results. The agenda includes approval of results for the quarter and half-year ended September 30, 2026.
Sep 30 2026 19:25:42
Novartis India Ltd - 500672 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Novartis India held an investor meet outlining its strategic roadmap, aiming to double revenues in the next 4-5 years. The company will focus on six key therapy areas, expand its distribution network, and pursue M&A, recently acquiring Minipress XL and an ophthalmology portfolio. Short-term costs are expected for this commercial reset.
Sep 15 2026 15:59:13
Novartis India Ltd - 500672 - Intimation Regarding The Acquisition Of Trademarks "Minipress" And "Minipres" From Pfizer Inc. USA And Pfizer Products Inc. USA, The Same Is Approved By The Board Of Directors Of The Company At Their Board Meeting Held Today I.E. September 07, 2026
Novartis has acquired the 'Minipress' and 'Minipres' trademarks along with related intellectual property from Pfizer Inc. USA for Rs. 1,250 crore. This strategic move aims to bolster Novartis's portfolio in the hypertension and BPH therapeutic areas, leveraging established brands.
Sep 07 2026 11:24:31
Novartis India Management
| Name | Position |
|---|---|
| Chandni Maru | Company Secretary & Compliance Officer |
| Christopher Snook | Chairperson |
Novartis India Similar Stocks
Novartis India FAQs
Open Your Free
Demat Account Now!
AMC for First Year
Auto Square Off Charges
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools

Open Your Free
Demat Account Now!
AMC For First Year
Account Opening Fee
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools
Invest in NOVARTIND
Account Opening Fee AMC for 1st Year Auto Square Off Charges Call & Trade
+ Free 1st Year AMC